Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza

Rivals’ Revenues Could Overtake Spinraza In 2023

 
• By Andrew McConaghie
  
Zolgensma
Novartis's Zolgensma (pictured) and Roche's Evrysdi are gaining ground on Biogen's Spinraza • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip